Late Breaking Clinical Trial

Effects of Interleukin-6 Inhibition with Ziltivekimab on Biomarkers of Inflammation and Thrombosis Among Patients at High Atherosclerotic Risk:

A Randomized, Double-Blind Phase 2 Trial

Paul Ridker, Matt Devalaraja, Florian Baeres, Mads Engelmann, G Kees Hovingh, Milana Ivkovic, Larry Lo, Douglas Kling, Pablo Pergola, Dominic Raj, Peter Libby, and Michael Davidson on behalf of the RESCUE Investigators
Conflicts of Interest:

The RESCUE trial was supported by Corvidia and Novo Nordisk

Dr. Ridker has received investigator-initiated research grants from Kowa, Novartis, Pfizer, AstraZeneca, Amarin, NHLBI, NCI

Dr. Ridker has served as a consultant to Corvidia, Novo Nordisk, Inflazome, Novartis, Amgen, Merck, Jansen, Agepha, Flame, and CiviBio.

Dr. Ridker is listed as a co-inventor on patents related to the use of inflammatory biomarkers in CVD and diabetes that are no longer active.
Moving Beyond Cholesterol: Can Targeted Anti-Cytokine Therapy Reduce Cardiovascular Event Rates and Prolong Life?

Focus on the Interleukin-1 (IL-1β) to Interleukin-6 (IL-6) to CRP Pathway

Ridker PM. Circulation 2020;141:787-789
Anti-Cytokine Therapy for Chronic Stable Atherothrombosis

In 2017, the CANTOS trial demonstrated that inflammation inhibition targeting the central IL-1β to IL-6 to hsCRP pathway of innate immunity reduces cardiovascular event rates independent of LDL lowering.

NEJM 2017;377:1119-31

Moreover, in CANTOS, the magnitude of clinical benefit was directly related to the magnitude of downstream IL-6 reduction achieved by individual trial participants, suggesting that IL-6 may be the primary target for atheroprotection.

Lancet 2018;391:319-28; EHJ 2018;38:3499-3507

Ridker PM, Rane M. Interleukin-6 Signaling and Anti-Interleukin-6 Therapeutics in Cardiovascular Disease Circulation Research 2021
IL-6 and Chronic Stable Atherothrombosis: Experimental Findings

Pivotal cytokine of innate immunity and vascular biology:

- Orchestrates hepatic synthesis of acute phase reactants
- Activates endothelial cells, increased expression of ICAM, VCAM
- Activates matrix metalloproteinases that weaken the fibrous cap
- Promotes lymphocyte proliferation and differentiation
- Increases coagulation, induction of monocyte TF expression

In murine intervention models:

- Exogenous IL-6 increases fatty streak development
- Murine anti-IL-6 receptor antibodies slow atherosclerotic progression

Ridker PM, Rane M. Interleukin-6 Signaling and Anti-Interleukin-6 Therapeutics in Cardiovascular Disease
Circulation Research 2021

Akita et al, Front Cardiovasc Med 2017;4:84
Plasma levels of IL-6 and hsCRP predict cardiovascular risk with a magnitude of effect greater than that of LDL-C.

Mendelian Randomization studies indicate that genetic variants in the IL-6 receptor signaling pathway associate with lifelong risks of coronary heart disease suggesting that IL-6 is likely to be causal for atherosclerotic progression.

GWAS and PHEWAS data affirm a role of IL-6 signaling in multiple forms of atherosclerosis including myocardial infarction, peripheral arterial disease, and aortic aneurysm formation.
Based on these observations, it has been hypothesized that direct inhibition of IL-6 might have the potential to maximize anti-inflammatory atherosclerotic benefit.

One agent under evaluation is ziltivekimab, a narrow spectrum fully human monoclonal antibody targeting the IL-6 ligand that is being developed specifically for atherosclerosis.
To address these issues, we conducted a randomized, double-blind, placebo-controlled phase 2 trial to evaluate the effects of ziltivekimab on multiple biomarkers of inflammation and thrombosis.

We focused on patients at high cardiovascular risk with chronic kidney disease (CKD) and elevated hsCRP, a group with considerable unmet clinical need where IL-6 levels correlate with severity of renal impairment as well as level of atherosclerotic risk.
RESCUE: Trial Conduct and Participant Flow

**Trial Conduct**
June 17, 2019 - January 14, 2020
40 US clinical sites
264 participants randomized
SC placebo or SC ziltivekimab 7.5, 15, 30 q 4 weeks

**Major Inclusion Criteria**
- Age ≥ 18 years
- Stage 3 – 5 CKD
- hsCRP ≥ 2 mg/L

**Primary Endpoint**
Percent change in hsCRP from baseline to 12 weeks

**Secondary Endpoints**
Percent change in fibrinogen, haptoglobin, SAA, sPLA2, Lp(a), and lipid levels

**Major Exclusion Criteria**
- ANC < 2 x 10^9
- Platelet Count < 120 x 10^9
- Spot urine to creatinine ratio > 4
- Active TB or History of HIV, hepatitis B, hepatitis C

12 Week Primary Endpoint
24 Week Full Treatment and Safety Period
## RESCUE: Baseline Clinical Characteristics

<table>
<thead>
<tr>
<th></th>
<th>Placebo (N=66)</th>
<th>Ziltivekimab 7.5mg (N=66)</th>
<th>Ziltivekimab 15mg (N=66)</th>
<th>Ziltivekimab 30mg (N=66)</th>
<th>All Participants (N = 264)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years, median)</td>
<td>66.0</td>
<td>70.0</td>
<td>65.5</td>
<td>68.0</td>
<td>68.0</td>
</tr>
<tr>
<td>Female, (%)</td>
<td>44</td>
<td>48</td>
<td>55</td>
<td>48</td>
<td>49</td>
</tr>
<tr>
<td>BMI (kg/m², median)</td>
<td>35.9</td>
<td>32.7</td>
<td>34.4</td>
<td>34.8</td>
<td>34.4</td>
</tr>
<tr>
<td>Diabetes, (%)</td>
<td>76</td>
<td>62</td>
<td>73</td>
<td>73</td>
<td>71</td>
</tr>
<tr>
<td>Hypertension, (%)</td>
<td>94</td>
<td>91</td>
<td>91</td>
<td>91</td>
<td>92</td>
</tr>
<tr>
<td>ASCVD, (%)</td>
<td>56</td>
<td>44</td>
<td>41</td>
<td>50</td>
<td>48</td>
</tr>
<tr>
<td>Statin Use, (%)</td>
<td>68</td>
<td>67</td>
<td>68</td>
<td>68</td>
<td>68</td>
</tr>
<tr>
<td>CKD Stage, (%)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>3a</td>
<td>29</td>
<td>24</td>
<td>35</td>
<td>29</td>
<td>29</td>
</tr>
<tr>
<td>3b</td>
<td>35</td>
<td>45</td>
<td>44</td>
<td>39</td>
<td>41</td>
</tr>
<tr>
<td>4</td>
<td>26</td>
<td>24</td>
<td>15</td>
<td>26</td>
<td>23</td>
</tr>
<tr>
<td>5</td>
<td>8</td>
<td>5</td>
<td>6</td>
<td>5</td>
<td>6</td>
</tr>
<tr>
<td>eGFR (ml/min/1.73m², median)</td>
<td>38.0</td>
<td>35.3</td>
<td>37.3</td>
<td>37.2</td>
<td>36.8</td>
</tr>
<tr>
<td>hsCRP (mg/L, median)</td>
<td>5.8</td>
<td>5.5</td>
<td>5.7</td>
<td>5.8</td>
<td>5.7</td>
</tr>
<tr>
<td>IL-6 (pg/ml, median)</td>
<td>5.2</td>
<td>4.9</td>
<td>5.1</td>
<td>6.6</td>
<td>5.6</td>
</tr>
</tbody>
</table>
RESCUE: Primary Result – Change in hsCRP at 12 weeks

A

12 weeks from randomization

-4%  -77%  -88%  -92%  -100%

Median % change in hsCRP (mg/L)

B

Wash out*

hsCRP median (mg/L, log10)

<table>
<thead>
<tr>
<th>Weeks from randomization</th>
<th>Placebo (n)</th>
<th>Zilti 7.5 mg (n)</th>
<th>Zilti 15 mg (n)</th>
<th>Zilti 30 mg (n)</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>66</td>
<td>64</td>
<td>62</td>
<td>66</td>
</tr>
<tr>
<td>3</td>
<td>64</td>
<td>64</td>
<td>64</td>
<td>66</td>
</tr>
<tr>
<td>6</td>
<td>63</td>
<td>62</td>
<td>61</td>
<td>66</td>
</tr>
<tr>
<td>9</td>
<td>57</td>
<td>58</td>
<td>61</td>
<td>66</td>
</tr>
<tr>
<td>12</td>
<td>46</td>
<td>52</td>
<td>49</td>
<td>50</td>
</tr>
<tr>
<td>16</td>
<td>35</td>
<td>39</td>
<td>40</td>
<td>39</td>
</tr>
<tr>
<td>20</td>
<td>27</td>
<td>28</td>
<td>28</td>
<td>29</td>
</tr>
<tr>
<td>22</td>
<td>31</td>
<td>32</td>
<td>32</td>
<td>30</td>
</tr>
<tr>
<td>24</td>
<td>49</td>
<td>52</td>
<td>51</td>
<td>53</td>
</tr>
</tbody>
</table>

C

>50% reduction in hsCRP and on-treatment hsCRP < 2 mg/L

Proportion of patients %

12 weeks from randomization

Placebo  Zilti 7.5 mg  Zilti 15 mg  Zilti 30 mg

****P<0.001
RESCUE: Waterfall Plots Demonstrate Dose-Dependent Effects of Ziltivekimab on Change in hsCRP
RESCUE: Secondary Biomarker Results

**Fibrinogen**
- Placebo: -2%
- Zilti 7.5 mg: -25%
- Zilti 15 mg: -25%
- Zilti 30 mg: -37%

**Haptoglobin**
- Placebo: -3%
- Zilti 7.5 mg: -30%
- Zilti 15 mg: -40%
- Zilti 30 mg: -56%

**Serum Amyloid A**
- Placebo: 2%
- Zilti 7.5 mg: -40%
- Zilti 15 mg: -50%
- Zilti 30 mg: -42%

**sPLA2**
- Placebo: 0%
- Zilti 7.5 mg: -27%
- Zilti 15 mg: -41%
- Zilti 30 mg: -49%

**Lipoprotein (a)**
- Placebo: 0%
- Zilti 7.5 mg: -16%
- Zilti 15 mg: -20%
- Zilti 30 mg: -25%

**Apo B : Apo A Ratio**
- Placebo: -2%
- Zilti 7.5 mg: 0%
- Zilti 15 mg: 0%
- Zilti 30 mg: -5%

* **** P< 0.001
### RESCUE: Safety Analysis

<table>
<thead>
<tr>
<th>Event</th>
<th>Placebo (N=65)</th>
<th>Ziltivekimab 7.5mg (N=65)</th>
<th>Ziltivekimab 15mg (N=66)</th>
<th>Ziltivekimab 30mg (N=65)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Serious injection-related reactions, %</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Any ALT or AST &gt; 3x ULN, %</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Any serious infection, %</td>
<td>5</td>
<td>11</td>
<td>5</td>
<td>3</td>
</tr>
<tr>
<td>Anaphylaxis, %</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Sustained neutropenia*, %</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Grade 1 (&lt;2000–1500 cells/mm³)</td>
<td>2</td>
<td>2</td>
<td>3</td>
<td>2</td>
</tr>
<tr>
<td>Grade 2 (&lt;1500–1000 cells/mm³)</td>
<td>0</td>
<td>2</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Grade 3 or 4</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Sustained thrombocytopenia*, n (%)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Grade 1 (&lt;100,000–75,000 cells/mm³)</td>
<td>0</td>
<td>0</td>
<td>3</td>
<td>2</td>
</tr>
<tr>
<td>Grade 2, 3, or 4</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
</tbody>
</table>
RESCUE summary

• Ziltivekimab, a novel IL-6 ligand inhibitor, markedly reduced multiple biomarkers of systemic inflammation and thrombosis known to promote the atherothrombotic process, including hsCRP, fibrinogen, SAA, sPLA2, and Lp(a).

• The magnitude of change with ziltivekimab on hsCRP was nearly twice as large in RESCUE as that observed in the CANTOS trial of canakinumab where cardiovascular event rates were reduced by 15 to 20 percent.

• The anti-inflammatory benefits of ziltivekimab were achieved with minimal evidence of bone marrow suppression, infectious risk, hepatic toxicity, or change in atherogenic lipid levels.

• These phase II data suggest that ziltivekimab may be unique among currently available IL-6 inhibitors and strongly supports its use in future cardiovascular outcome trials.
Ziltivekimab Cardiovascular Outcomes Study (ZEUS)

**ZEUS: Phase 3a trial design**
CVOT in ASCVD patients with CKD treated with ziltivekimab

6200 patients
- ASCVD
- CKD stage 3-4
- hsCRP ≥2 mg/L

Randomisation
(1:1)

**Ziltivekimab once-monthly 15 mg + standard of care**

**Placebo once-monthly + standard of care**

**Primary endpoint**
- Time to the first occurrence of MACE (CV death, non-fatal MI or non-fatal stroke)

**Secondary endpoints**
- Time to first occurrence of expanded MACE (CV death, non-fatal MI, non-fatal stroke or urgent coronary revascularisation)
- Number of hospitalisations for HF or urgent HF visits
- Time to all cause death
- Time to first occurrence of composite CKD endpoint (≥ 40% GFR reduction, kidney death, CKD stage 5, dialysis treatment or kidney transplant)

**Trial information**
- Double-blinded
- Trial start in 2021
- Event-driven

**Why CKD with elevated hsCRP?**
- Large unmet need
- Very high cardiovascular risk
- Crucial biologic state
  - LDL-C less relevant for outcomes
  - Inflammation more relevant for outcomes
- Colchicine is relatively contraindicated in CKD
THE LANCET

IL-6 inhibition with ziltivekimab in patients at high atherosclerotic risk: a double-blind, randomised, placebo-controlled, phase 2 trial

Paul M Ridker, Matt Devalaraja, Florian M M Baeres, Mads D M Engelmann, G Kees Hovingh, Milana Ivkovic, Larry Lo, Douglas Kling, Pablo Pergola, Dominic Raj, Peter Libby, Michael Davidson, on behalf of the RESCUE Investigators

Lancet 2021 (on-line ACC)